不同抗逆转录病毒药物配发间隔改善HIV患者结局(INTERVAL研究):一项随机对照试验的研究方案
该研究为在马拉维和赞比亚开展的非盲整群随机对照试验,纳入8200名18岁以上稳定的HIV感染抗逆转录病毒治疗(ART)患者,比较标准照护、3个月和6个月三种ART配发间隔对留存照护(主要结局)、病毒学抑制和成本效果的影响,随访至12、24和36个月,并对240名参与者和180名提供者进行定性访谈评估可行性与可接受性。
要点
- 首个比较6个月与3个月ART配发间隔的随机研究,对象为马拉维和赞比亚稳定HIV感染者。
- 30个整群按国家、机构类型和ART队列规模匹配后随机分配至标准照护、3个月或6个月配发组。
- 结局在12、24和36个月测量,包括留存照护(主要结局)、病毒学抑制和成本效果。
核心结论
- 该研究将首次在马拉维和赞比亚稳定HIV感染者中比较6个月与3个月ART配发间隔,聚焦留存、病毒学抑制和成本效果等与国家项目相关的结局,结果有助于资源有限卫生系统理解不同配发间隔的结局范围并帮助告知卫生政策决策。
研究设计与样本
- 非盲整群随机对照试验,在马拉维和赞比亚的8200名18岁及以上稳定HIV感染ART患者中开展,比较标准照护、3个月和6个月三种ART配发间隔。
- 30个整群按国家、机构类型和ART队列规模匹配后随机分配至三个研究组,参与者在12、24和36个月测量结局。
- 另对240名参与者和180名提供者进行定性访谈,评估不同ART配发间隔的可行性与可接受性。
主要发现
- 研究方案阶段无结局数据报告;主要结局为留存照护,次要结局包括病毒学抑制和成本效果。
关键数值与推荐
- 主要结局为留存照护,同时评估病毒学抑制和成本效果,随访测量点为12、24和36个月。
- 试验注册于ClinicalTrials.gov(NCT03101592,2017年3月18日注册)和泛非临床试验注册库(PACTR201706002336105,2017年6月2日注册)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Requirements for frequent dispensing of antiretroviral therapy (ART) place demands on health systems and can lead to suboptimal adherence and disengagement in care for patients due to the time and cost of frequent clinic visits. Rigorous data are needed to define optimal ART dispensing strategies and to evaluate the impact of a longer medication supply on retention and virologic suppression and determine whether this strategy lowers costs for both the patient and the health system. To date, no randomized studies have tested the benefits of 6-month dispensing of ART compared to 3-month and standard of care approaches. METHODS: This study will be an unblinded cluster-randomized, matched controlled trial conducted among 8200 stable, HIV-infected individuals age 18 years and older on ART in Malawi and Zambia, to compare three ART dispensing intervals on the outcomes of retention in care (primary outcome), virologic suppression, and cost-effectiveness. Thirty clusters will be matched according to country, facility type, and ART cohort size and randomized to one of three study arms: standard of care, 3-month dispensing, and 6-month dispensing. Study participants will be followed, and outcomes will be measured at 12, 24, and 36 months. A subset of participants (n = 240) and providers (n = 180) will also participate in qualitative interviews to evaluate feasibility and acceptability of different ART dispensing intervals. DISCUSSION: This study will be the first to compare 6-month and 3-month ART dispensing intervals for stable, HIV-infected individuals in Malawi and Zambia. We focus on outcomes relevant to country programs, including retention, virologic suppression, and cost-effectiveness. Results from the study will help resource-limited health systems better understand the full scope of outcomes resulting from various ART dispensing intervals and help to inform health policy decisions. TRIAL REGISTRATION: ClinicalTrials.gov, NCT03101592 . Registered on 18 March 2017. Pan African Clinical Trials, PACTR201706002336105 . Registered on 2 June 2017.
引用
- Hoffman R, Bardon A, Rosen S, et al. Varying intervals of antiretroviral medication dispensing to improve outcomes for HIV patients (The INTERVAL Study): study protocol for a randomized controlled trial. Trials. 2017. PMID: 29029644. doi:10.1186/s13063-017-2177-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。